Stock analysts at HC Wainwright initiated coverage on shares of Palatin Technologies (NASDAQ:PTN – Get Free Report) in a report issued on Friday, Benzinga reports. The brokerage set a “buy” rating and a $12.00 price target on the stock.
Palatin Technologies Price Performance
Palatin Technologies Company Profile
Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications.
The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Featured Stories
- Five stocks we like better than Palatin Technologies
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
